AIS Healthcare, a Market Leader in Infusion Care Management
With the increasing prevalence of chronic diseases, such as cancer, diabetes, and autoimmune disorders, the need for targeted drug delivery (TDD) and infusion management solutions has created a lucrative market worth more than $14 billion. AIS Healthcare, a medical services provider with locations in Alabama, Florida, Georgia, Maryland, Mississippi, and Texas, is quickly becoming a leader in this market.
The Advanced Infusion Care division of AIS Healthcare provides smart team-based solutions for patients in need of subcutaneous and intravenous administration of medications such as Asceniv, HyQvia, Xembify, and many others. Members of the AIC team include managers, clinical pharmacists, nurses, and phlebotomy specialists who handle everything from patient intake to IV formulation and infusion therapy. In other words, AIC can be a strategic partner for clinical practices as well as managed healthcare organizations.
URAC Certification
In March 2023, AIS Healthcare received a coveted certification issued by the Utilization Review Accreditation Commission (URAC) for specialty pharmaceutical services at the company’s formulation centers across five states. The URAC accreditation program for specialty pharmacies is designed to help specialty pharmacies demonstrate their commitment to quality and accountability.
All AIC locations are now recognized by URAC as quality providers of healthcare services. What this means for patients who receive vital therapies such as immunoglobulin infusions is that they can receive this treatment at home from a highly reputable practice. Patients and practitioners can take comfort in the fact that AIS Healthcare adheres to strict policies for all aspects of its operations. All of the company’s infusion centers are licensed and inspected at the state level.
The commitment to quality that AIS Healthcare observes starts with the recruiting, preparation, and retention of specialized nursing staff members. To this effect, Nurse Practitioner Natalie DeGroff, director of the Targeted Drug Delivery division, was selected in 2023 to join the Executive Leadership Program Cohort managed by the American Association of Nurse Practitioners. Along with 13 other nursing professionals, Ms. DeGroff will help develop national standards of excellence in nursing.
This selection is a clear example that AIS Healthcare is on the right track to becoming a leader in the infusion management sector.
